



# Shared Clinical Decision-Making PCV20 Vaccination for Adults 65 Years or Older

Adults 65 years of age or older have the option to receive PCV20 if they previously completed the pneumococcal vaccine series with both PCV13 and PPSV23 and meet the following criteria:

- Previously received one dose of PCV13 (but not PCV15 or PCV20) at any age
- Previously received all recommended doses of PPSV23 (including 1 dose of PPSV23 at or after the age of 65 years)

The determination to administer PCV20 is based on a shared clinical decision-making process (SCDM) between a patient and their healthcare provider. SCDM recommendations are optional and informed by the characteristics, values, and preferences of the patient, and the clinical discretion of the healthcare provider.

## If you discuss PCV20 vaccination with a patient 65 years or older who previously completed the pneumococcal vaccine series with both PCV13 and PPSV23:

### Remember:



PCV20 is not routinely recommended for these individuals as their risk of disease is lower due to prior vaccinations. Their remaining risk depends on

- Their risk for exposure to serotypes contained in PCV20
- The presence of underlying medical conditions or other risk factors that increase the risk of developing severe disease
- Time since last pneumococcal vaccination (i.e.,  $\geq 5$  years)

### Consider:



Increased risk of exposure to PCV20 serotypes may occur among persons

- Living in nursing homes or other long-term care facilities
- Living in areas with low pediatric pneumococcal conjugate vaccine uptake

If exposed, people with one or more of the following health issues are at increased risk of severe pneumococcal disease:

- Immunocompromising condition\*
- Cochlear implant
- Cerebrospinal fluid leak
- More than one of these chronic medical conditions: alcoholism; chronic heart, liver, or lung disease; cigarette smoking; or diabetes

Vaccine efficacy of both PCV13 and PPSV23 decreases with increasing time since vaccination.

### If you vaccinate:



If you and your patient decide PCV20 is appropriate, give one dose of PCV20 at least 5 years after their last pneumococcal vaccine dose.

PCV20 is safe unless a patient had a severe allergic reaction to a:

- Previous dose of PCV13 or any vaccine containing diphtheria-toxoid
- Vaccine component (PCV20 or any vaccine containing diphtheria-toxoid)

\* Chronic renal failure, nephrotic syndrome, immunodeficiency, iatrogenic immunosuppression, generalized malignancy, HIV, Hodgkin disease, leukemia, lymphoma, multiple myeloma, solid organ transplant, congenital or acquired asplenia, sickle cell disease, or other hemoglobinopathies.

### Additional Information:

CDC Adult Immunization Schedule:

[www.cdc.gov/vaccines/schedules/hcp/imz/adult.html](http://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html)

CDC PneumoRecs VaxAdvisor App for Clinicians:

[www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html](http://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html)

CDC Pneumococcal Vaccine Information:

[www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html](http://www.cdc.gov/vaccines/vpd/pneumo/hcp/index.html)



U.S. Department of  
Health and Human Services  
Centers for Disease  
Control and Prevention